Therapeutic gene delivery using bioreducible polymers

Archives of Pharmacal Research

Volumn 37, Issue 1, 2014, Pages 31-42

  Ryu, Kitae ^a   Kim, Tae Il ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Bioreducible polymer; Cancer; Diabetes; Gene delivery; Myocardial infarction; Therapeutic gene

Indexed keywords

ERYTHROPOIETIN; FAS ANTIGEN; GELATINASE A; GLUCAGON LIKE PEPTIDE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; POLYMER; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; DNA; RNA;

ANGIOGENESIS; CHRONIC KIDNEY DISEASE; GENE TARGETING; HEART INFARCTION; HUMAN; HYPERPLASIA; INFLAMMATORY BOWEL DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIA; NEOINTIMA HYPERPLASIA; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; STEM CELL TRANSPLANTATION; THERAPY; ANIMAL; CARDIOVASCULAR DISEASES; CELL NUCLEUS; CHEMISTRY; DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; GENETICS; METABOLISM; NANOMEDICINE; NEOPLASMS; OXIDATION REDUCTION REACTION; PROCEDURES; RNA INTERFERENCE;

ANIMALS; CARDIOVASCULAR DISEASES; CELL NUCLEUS; DIABETES MELLITUS; DNA; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; NANOMEDICINE; NEOPLASMS; OXIDATION-REDUCTION; POLYMERS; RNA; RNA INTERFERENCE;

EID: 84892941473     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0275-3     Document Type: Review

References (114)

1. Ahrén, B. 2011. The future of incretin-based therapy: Novel avenues-novel targets. Diabetes, Obesity and Metabolism 13(Suppl 1): 158-166.
2. Arnér, E.S., and A. Holmgren. 2000. Physiological functions of thioredoxin and thioredoxin reductase. European Journal of Biochemistry 267: 6102-6109.
3. Aspord, C., S. Rome, and C. Thivolet. 2004. Early events in islets and pancreatic lymph nodes in autoimmune diabetes. Journal of Autoimmunity 23: 27-35.
4. Atkinson, M.A., and G.S. Eisenbarth. 2001. Type 1 diabetes: New perspectives on disease pathogenesis and treatment. Lancet 358: 221-229.
5. Atkinson, M.A., and N.K. Maclaren. 1994. The pathogenesis of insulin-dependent diabetes mellitus. New England Journal of Medicine 331: 1428-1436.
6. Beloor, J., C.S. Choi, H.Y. Nam, M. Park, S.H. Kim, A. Jackson, K.Y. Lee, S.W. Kim, P. Kumar, and S.-K. Lee. 2012. Arginineengrafted biodegradable polymer for the systemic delivery of therapeutic siRNA. Biomaterials 33: 1640-1650.
7. Bhang, S.H., S.W. Cho, W.G. La, T.J. Lee, H.S. Yang, A.Y. Sun, S.H. Baek, J.W. Rhie, and B.S. Kim. 2011. Angiogenesis in ischemic tissue produced by spheroid grafting of human adipose-derived stromal cells. Biomaterials 32: 2734-2747.
8. Bianco, P., M. Riminucci, S. Gronthos, and P.G. Robey. 2001. Bone marrow stromal stem cells: Nature, biology, and potential applications. Stem Cells 19: 180-192.
9. Blackburn, E.H. 1992. Telomerases. Annual Review of Biochemistry 61: 113-129.
10. Blevins, K.S., J.H. Jeong, M. Ou, J.H. Brumbach, and S.W. Kim. 2012. EphA2 targeting peptide tethered bioreducible poly(cystamine bisacrylamide-diamino hexane) for the delivery of therapeutic pCMV-RAE-1c to pancreatic islets. Journal of Controlled Release 158: 115-122.
11. Brewster, L.P., E.M. Brey, and H.P. Greisler. 2006. Cardiovascular gene delivery: The good road is awaiting. Advanced Drug Delivery Reviews 58: 604-629.
12. Brubaker, P.L. 2010. Minireview: Update on incretin biology: Focus on glucagon-like peptide-1. Endocrinology 151: 1984-1989.
13. Brülisauer, L., N. Kathriner, M. Prenrecaj, M.A. Gauthier, and J.-C. Leroux. 2012. Tracking the bioreduction of disulfide-containing cationic dendrimers. Angewandte Chemie International Edition 51: 12454-12458.
14. Burgess, S.J., K. Maasho, M. Masilamani, S. Narayanan, F. Borrego, and J.E. Coligan. 2008. The NKG2D receptor: Immunobiology and clinical implications. Immunologic Research 40: 18-34.
15. Buteau, J., R. Roduit, S. Susini, and M. Prentki. 1999. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42: 856-864.
16. Caplan, A.I., and J.E. Dennis. 2006. Mesenchymal stem cells as trophic mediators. Journal of Cellular Biochemistry 98: 1076-1084.
17. Chen, C.-J., J.-C. Wang, E.-Y. Zhao, L.-Y. Gao, Q. Feng, X.-Y. Lin, Z.-X. Zhao, X.-F. Ma, W.-J. Hou, L.-R. Zhang, W.-L. Lu, and Q. Zhang. 2013. Self-assembly cationic nanoparticles based on cholesterol-grafted bioreducible poly(amidoamine) for siRNA delivery. Biomaterials 34: 5303-5316.
18. Chenevix-Trench, G., N.G. Martin, and K.A. Ellem. 1990. Gene expression in melanoma cell lines and cultured melanocytes: Correlation between levels of c-src-1, c-myc and p53. Oncogene 5: 1187-1193.
19. Chiu, C.W., H. Nozawa, and D. Hanahan. 2010. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. Journal of Clinical Oncology 28: 4425-4433.
20. Christensen, L.V., C.-W. Chang, J.W. Yockman, R. Conners, H. Jackson, Z. Zhong, J. Feijen, D.A. Bull, and S.W. Kim. 2007. Reducible poly(amido ethylenediamine) for hypoxia-inducible VEGF delivery. Journal of Controlled Release 118: 254-261.
21. Cohen, R.D., J.F. Tsang, and S.B. Hanauer. 2000. Infliximab in Crohn's disease: First anniversary clinical experience. American Journal of Gastroenterology 95: 3469-3477.
22. Creutzfeldt, W.O., N. Kleine, B. Willms, C. Orskov, J.J. Holst, and M.A. Nauck. 1996. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 19: 580-586.
23. De Vries, C., J.A. Escobedo, H. Ueno, K. Houck, N. Ferrara, and L.T. Williams. 1992. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991.
24. Engelmann, M.G., and W.M. Franz. 2006. Stem cell therapy after myocardial infarction: Ready for clinical application? Current Opinion in Molecular Therapeutics 8: 396-414.
25. Eschbach, J.W., and J.W. Adamson. 1985. Anemia of end-stage renal disease (ESRD). Kidney International 28: 1-5.
26. Eschbach, J.W., J.C. Egrie, M.R. Downing, J.K. Browne, and J.W. Adamson. 1987. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. New England Journal of Medicine 316: 73-78.
27. Etzerodt, A., M.B. Maniecki, J.H. Graversen, H.J. Møller, V.P. Torchilin, and S.K. Moestrup. 2012. Efficient intracellular drugtargeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163. Journal of Controlled Release 160: 72-80.
28. Florinas, S., H.Y. Nam, and S.W. Kim. 2013. Enhanced siRNA delivery using a combination of an arginine-grafted bioreducible polymer, ultrasound, and microbubbles in cancer cells. Molecular Pharmaceutics 10: 2021-2030.
29. Go, Y.M., and D.P. Jones. 2008. Redox compartmentalization in eukaryotic cells. Biochimica et Biophysica Acta 1780: 1273-1290.
30. Grover, R., D.A. Ross, P.I. Richman, B. Robinson, and G.D. Wilson. 1996. C-Myc oncogene expression in human melanoma and its relationship with tumour antigenicity. European Journal of Surgical Oncology 22: 342-346.
31. Hamar, P., E. Song, G. Kokeny, A. Chen, N. Ouyang, and J. Lieberman. 2004. Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proceedings of the National Academy of Sciences of the United States of America 101: 14883-14888.
32. Herbert, B.-S., A.E. Pitts, S.I. Baker, S.E. Hamilton, W.E. Wright, J.W. Shay, and D.R. Corey. 1999. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proceedings of the National Academy of Sciences of the United States of America 96: 14276-14281.
33. Jeong, J.H., S.W. Kim, and T.G. Park. 2007. Molecular design of functional polymers for gene therapy. Progress in Polymer Science 32: 1239-1274.
34. Jere, D., R. Arote, H.L. Jiang, Y.K. Kim, M.H. Cho, and C.S. Cho. 2009. Bioreducible polymers for efficient gene and siRNA delivery. Biomedical Materials 4: 025020.
35. Joo, W.S., J.H. Jeong, K. Nam, K.S. Blevins, M.E. Salama, and S.W. Kim. 2012. Polymeric delivery of therapeutic RAE-1 plasmid to the pancreatic islets for the prevention of type 1 diabetes. Journal of Controlled Release 162: 606-611.
36. Katsaros, K.M., S.P. Kastl, G. Zorn, G. Maurer, J. Wojta, K. Huber, G. Christ, and W.S. Speidl. 2010. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and-9. JACC Cardiovascular Interventions 3: 90-97.
37. Kendall, R.L., G. Wang, and K.A. Thomas. 1996. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochemical and Biophysical Research Communications 226: 324-328.
38. Kim, T.I., M. Ou, M. Lee, and S.W. Kim. 2009a. Arginine-grafted bioreducible poly(disulfide amine) for gene delivery systems. Biomaterials 30: 658-664.
39. Kim, T.I., and S.W. Kim. 2011. Bioreducible polymers for gene delivery. Reactive and Functional Polymers 71: 344-349.
40. Kim, T.I., M. Lee, and S.W. Kim. 2012a. Efficient GLP-1 gene delivery using two-step transcription amplification plasmid system with a secretion signal peptide and arginine-grafted bioreducible polymer. Journal of Controlled Release 157: 243-248.
41. Kim, W.J., J.W. Yockman, M. Lee, J.H. Jeong, Y.-H. Kim, and S.W. Kim. 2005. Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis. Journal of Controlled Release 106: 224-234.
42. Kim, W.J., J.W. Yockman, J.H. Jeong, L.V. Christensen, M. Lee, Y.-H. Kim, and S.W. Kim. 2006. Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMVsFlt-1 complexes in tumor-bearing mice. Journal of Controlled Release 114: 381-388.
43. Kim, S.H., J.H. Jeong, T.I. Kim, S.W. Kim, and D.A. Bull. 2009b. VEGF siRNA delivery system using arginine-grafted bioreducible poly(disulfide amine). Molecular Pharmaceutics 6: 718-726.
44. Kim, P.-H., M. Lee, and S.W. Kim. 2012b. Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model. Journal of Controlled Release 162: 9-18.
45. Kirkpatrick, K.L., G. Clark, M. Ghilchick, R.F. Newbold, and K. Mokbel. 2003. hTERT mRNA expression correlates with telomerase activity in human breast cancer. European Journal of Surgical Oncology 29: 321-326.
46. Kriegel, C., and M. Amiji. 2011. Oral TNF-a gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. Journal of Controlled Release 150: 77-86.
47. Kuppusamy, P., M. Afeworki, R.A. Shankar, D. Coffin, M.C. Krishna, S.M. Hahn, J.B. Mitchell, and J.L. Zweier. 1998. In vivo electron paramagnetic resonance imaging of tumor heterogeneity and oxygenation in a murine model. Cancer Research 58: 1562-1568.
48. Kuzuya, M., S. Kanda, T. Sasaki, N. Tamaya-Mori, X.W. Cheng, T. Itoh, S. Itohara, and A. Iguchi. 2003. Deficiency of gelatinase a suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation 108: 1375-1381.
49. Laroui, H., A.L. Theiss, Y. Yan, G. Dalmasso, H.T. Nguyen, S.V. Sitaraman, and D. Merlin. 2011. Functional TNFa gene silencing mediated by polyethyleneimine/TNFa siRNA nanocomplexes in inflamed colon. Biomaterials 32: 1218-1228.
50. Lee, M., M. Bikram, S. Oh, D.A. Bull, and S.W. Kim. 2004. Sp1-dependent regulation of the RTP801 promoter and its application to hypoxia-inducible VEGF plasmid for ischemic disease. Pharmaceutical Research 21: 736-741.
51. Lee, M., S. Oh, C.H. Ahn, S.W. Kim, B.D. Rhee, and K.S. Ko. 2006. An efficient GLP-1 expression system using two-step transcription amplification. Journal of Controlled Release 115: 316-321.
52. Lee, D., D. Kim, H. Mok, J.H. Jeong, D. Choi, and S.H. Kim. 2012a. Bioreducible crosslinked polyelectrolyte complexes for MMP-2 siRNA delivery into human vascular smooth muscle cells. Pharmaceutical Research 29: 2213-2224.
53. Lee, Y., H.Y. Nam, J. Kim, M. Lee, J.W. Yockman, S.K. Shin, and S.W. Kim. 2012b. Human erythropoietin gene delivery using an arginine-grafted bioreducible polymer system. Molecular Therapy 20: 1360-1366.
54. Lee, Y., A.N. McGinn, C.D. Olsen, K. Nam, M. Lee, S.K. Shin, and S.W. Kim. 2013. Human erythropoietin gene delivery for cardiac remodeling of myocardial infarction in rats. Journal of Controlled Release 171: 24-32.
55. Li, Y., T. Hansotia, B. Yusta, F. Ris, P.A. Halban, and D.J. Drucker. 2003. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. Journal of Biological Chemistry 278: 471-478.
56. Lipsic, E., R.G. Schoemaker, P. van der Meer, A.A. Voors, D.J. van Veldhuisen, and W.H. van Gilst. 2006. Protective effects of erythropoietin in cardiac ischemia: From bench to bedside. Journal of the American College of Cardiology 48: 2161-2167.
57. Little, T.J., A.N. Pilichiewicz, A. Russo, L. Phillips, K.L. Jones, M.A. Nauck, J. Wishart, M. Horowitz, and C. Feinle-Bisset. 2006. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: Relationships with postprandial glycemic and insulinemic responses. Journal of Clinical Endocrinology and Metabolism 91: 1916-1923.
58. Liu, F., and L. Huang. 2002. Development of non-viral vectors for systemic gene delivery. Journal of Controlled Release 78: 259-266.
59. Luo, D., and W.M. Saltzman. 2000. Synthetic DNA delivery systems. Nature Biotechnology 18: 33-37.
60. Maasho, K., J. Opoku-Anane, A.I. Marusina, J.E. Coligan, and F. Borrego. 2005. NKG2D is a costimulatory receptor for human naive CD8? T cells. Journal of Immunology 174: 4480-4484.
61. Mahato, R.I., M. Lee, S. Han, A. Maheshwari, and S.W. Kim. 2001. Intratumoral delivery of p2CMVmIL-12 using water-soluble lipopolymers. Molecular Therapy 4: 130-138.
62. Maiese, K., F. Li, and Z.Z. Chong. 2005. New avenues of exploration for erythropoietin. JAMA 293: 90-95.
63. Malaisse, W.J., and P. Lebrun. 1990. Mechanisms of sulfonylureainduced insulin release. Diabetes Care 3: 9-17.
64. Markkanen, J.E., T.T. Rissanen, A. Kivelä, and S. Ylä-Herttuala. 2005. Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart-gene therapy. Cardiovascular Research 65: 656-664.
65. McGinn, A.N., H.Y. Nam, M. Ou, N. Hu, C.M. Straub, J.W. Yockman, D.A. Bull, and S.W. Kim. 2011. Bioreducible polymer-transfected skeletal myoblasts for VEGF delivery to acutely ischemic myocardium. Biomaterials 32: 942-949.
66. McGuire, M.J., K.N. Samli, S.A. Johnston, and K.C. Brown. 2004. In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo. Journal of Molecular Biology 342: 171-182.
67. Mikhail, N. 2008. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opinion on Investigational Drugs 17: 845-853.
68. Mistry, A.R., and C.A. O'Callaghan. 2007. Regulation of ligands for the activating receptor NKG2D. Immunology 121: 439-447.
69. Morin, G.B. 1989. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59: 521-529.
70. Nabel, E.G. 2003. Cardiovascular disease. New England Journal of Medicine 349: 60-72.
71. Nam, H.Y., A. McGinn, P.-H. Kim, S.W. Kim, and D.A. Bull. 2010. Primary cardiomyocyte-targeted bioreducible polymer for efficient gene delivery to the myocardium. Biomaterials 31: 8081-8087.
72. Nam, H.Y., Y. Lee, M. Lee, S.K. Shin, T.I. Kim, S.W. Kim, and D.A. Bull. 2012a. Erythropoietin gene delivery using an argininegrafted bioreducible polymer system. Journal of Controlled Release 157: 437-444.
73. Nam, K., H.Y. Nam, P.-H. Kim, and S.W. Kim. 2012b. Paclitaxelconjugated PEG and arginine-grafted bioreducible poly (disulfide amine) micelles for co-delivery of drug and gene. Biomaterials 33: 8122-8130.
74. Namgung, R., J. H. Brumbach, J. H. Jeong, J. W. Yockman, S. W. Kim, C. Lin, Z. Zhong, J. Feijen, J. F. Engbersen, and W. J. Kim. 2010. Dual bio-responsive gene delivery via reducible poly(amido amine) and survivin-inducible plasmid DNA. Biotechnology Letters 32: 755-764.
75. Nathan, D.M., E. Schreiber, H. Fogel, S. Mojsov, and J.F. Habener. 1992. Insulinotropic action of glucagon like peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15: 270-276.
76. Nauck, M.A., N. Kleine, C. Orskov, J.J. Holst, B. Willms, and W. Creutzfeldt. 1993. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (noninsulin-dependent) diabetic patients. Diabetologia 36: 741-744.
77. Nauck, M.A., M.M. Heimesaat, K. Behle, J.J. Holst, M.S. Nauck, R. Ritzel, M. Hüfner, and W.H. Schmiegel. 2002. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. Journal of Clinical Endocrinology and Metabolism 87: 1239-1246.
78. Nishiya, D., T. Omura, K. Shimada, R. Matsumoto, T. Kusuyama, S. Enomoto, H. Iwao, K. Takeuchi, J. Yoshikawa, and M. Yoshiyama. 2006. Effects of erythropoietin on cardiac remodeling after myocardial infarction. Journal of Pharmacological Science 101: 31-39.
79. Ochiya, T., S. Nagahara, A. Sano, H. Itoh, and M. Terada. 2001. Biomaterials for gene delivery: Atelocollagen-mediated controlled release of molecular medicines. Current Gene Therapy 1: 31-52.
80. Ogasawara, K., and L.L. Lanier. 2005. NKG2D in NK and T cellmediated immunity. Journal of Clinical Immunology 25: 534-540.
81. Ou, M., T.I. Kim, J.W. Yockman, B.A. Borden, D.A. Bull, and S.W. Kim. 2010. Polymer transfected primary myoblasts mediated efficient gene expression and angiogenic proliferation. Journal of Controlled Release 142: 61-69.
82. Pagani, F.D., H. DerSimonian, A. Zawadzka, K. Wetzel, A.S. Edge, D.B. Jacoby, J.H. Dinsmore, S. Wright, T.H. Aretz, H.J. Eisen, and K.D. Aaroson. 2003. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. Journal of the American College of Cardiology 41: 879-888.
83. Papa, A., G. Mocci, M. Bonizzi, C. Felice, G. Andrisani, G. Papa, and A. Gasbarrini. 2009. Biological therapies for inflammatory bowel disease: Controversies and future options. Expert Review of Clinical Pharmacology 2: 391-403.
84. Parsons, G.B., D.W. Souza, H. Wu, D. Yu, S.G. Wadsworth, R.J. Gregory, and D. Armentano. 2007. Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes. Gene Therapy 14: 38-48.
85. Plate, K.H., G. Breier, H.A. Weich, and W. Risau. 1992. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 359: 845-848.
86. Poeta, G.D.,A.Venditti, M.I. Del Principe, L.Maurillo, F.Buccisano,A. Tamburini, M.C. Cox, A. Franchi, A. Bruno, C. Mazzone, P. Panetta, G. Suppo, M. Masi, and S. Amadori. 2003. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 101: 2125-2131.
87. Rakhmilevich, A.L., K. Janssen, J. Turner, J. Culp, and N.-S. Yang. 1997. Cytokine gene therapy of cancer using gene gun technology: Superior antitumor activity of interleukin-12. Human Gene Therapy 11: 1303-1311.
88. Ranganath, L.R. 2008. Incretins: Pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. Journal of Clinical Pathology 61: 401-409.
89. Raulet, D.H. 2003. Roles of the NKG2D immunoreceptor and its ligands. Nature Reviews Immunology 3: 781-790.
90. Reinecke, H., E. Minami, V. Poppa, and C.E. Murry. 2004. Evidence for fusion between cardiac and skeletal muscle cells. Circulation Research 94: e56-e60.
91. Richard-Fiardo, P., E. Payen, R. Chèvre, J. Zuber, E. Letrou-Bonneval, Y. Beuzard, and B. Pitard. 2008. Therapy of anemia in kidney failure, using plasmid encoding erythropoietin. Human Gene Therapy 19: 331-342.
92. Sandborn, W.J. 2003. Strategies for targeting tumour necrosis factor in IBD. Best Practice & Research Clinical Gastroenterology 17: 105-117.
93. Schafer, F.Q., and G.R. Buettner. 2001. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radical Biology and Medicine 30: 1191-1212.
94. Shim, M.S., S.H. Bhang, K. Yoon, K. Choi, and Y. Xia. 2012. A bioreducible polymer for efficient delivery of Fas-silencing siRNA into stem cell spheroids and enhanced therapeutic angiogenesis. Angewandte Chemie (International ed. in English) 51: 11899-11903.
95. Smyth, M.J., M. Taniguchi, and S.E.A. Street. 2000. The anti-tumor activity of IL-12: Mechanisms of innate immunity that are model and dose dependent. Journal of Immunology 5: 2665-2670.
96. Son, S., R. Namgung, J. Kim, K. Singha, and W.J. Kim. 2012. Bioreducible polymers for gene silencing and delivery. Accounts of Chemical Research 45: 1100-1112.
97. Stephanou, A., T.M. Scarabelli, B.K. Brar, Y. Nakanishi, M. Matsumura, R.A. Knight, and D.S. Latchman. 2001. Induction of apoptosis and Fas receptor/Fas ligand expression by ischemia/ reperfusion in cardiac myocytes requires serine 727 of the STAT-1 transcription factor but not tyrosine 701. Journal of Biological Chemistry 276: 28340-28347.
98. Sun, Y.-X., X. Zeng, Q.F. Meng, X.Z. Zhang, S.X. Cheng, and R.X. Zhuo. 2008. The influence of RGD addition on the gene transfer characteristics of disulfide-containing polyethyleneimine/DNA complexes. Biomaterials 29: 4356-4365.
99. Suzuki, R., T. Takizawa, Y. Negishi, N. Utoguchi, and K. Maruyama. 2007. Effective gene delivery with liposomal bubbles and ultrasound as novel non-viral system. Journal of Drug Targeting 15: 531-537.
100. Tan, W., W. Zhang, A. Strasner, S. Grivennikov, J.Q. Cheng, R.M. Hoffman, and M. Karin. 2011. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKLRANK signalling. Nature 470: 548-553.
101. Van Belle, T.L., and M.G. von Herrath. 2009. The role of the activating receptor NKG2D in autoimmunity. Molecular Immunology 47: 8-11.
102. Wang, D., A.S. Narang, M. Kotb, A.O. Gaber, D.D. Miller, S.W. Kim, and R.I. Mahato. 2002. Novel branched poly(ethylenimine)-cholesterol water-soluble lipopolymers for gene delivery. Biomacromolecules 3: 1197-1207.
103. Wileman, T.E., M.R. Lennartz, and P.D. Stahl. 1986. Identification of the macrophage mannose receptor as a 175-kDa membrane protein. Proceedings of the National Academy of Sciences of the United States of America 83: 2501-2505.
104. Wu, G., Y.Z. Fang, S. Yang, J.R. Lupton, and N.D. Turner. 2004. Glutathione metabolism and its implications for health. Journal of Nutrition 134: 489-492.
105. Wu, Y., J. Deng, P.G. Rychahou, S. Qiu, B.M. Evers, and B.P. Zhou. 2009. Stabilization of snail by NF-kB is required for inflammation-induced cell migration and invasion. Cancer Cell 15: 416-428.
106. Xia, W., P. Wang, C. Lin, Z. Li, X. Gao, G. Wang, and X. Zhao. 2012. Bioreducible polyethylenimine-delivered siRNA targeting human telomerase reverse transcriptase inhibits HepG2 cell growth in vitro and in vivo. Journal of Controlled Release 157: 427-436.
107. Xiao, B., and D. Merlin. 2012. Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease. Expert Opinion on Drug Delivery 9: 1393-1407.
108. Xiao, B., H. Laroui, S. Ayyadurai, E. Viennois, M.A. Charania, Y. Zhang, and D. Merlin. 2013a. Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-a RNA interference for IBD therapy. Biomaterials 34: 7471-7482.
109. Xiao, J., X. Duan, Q. Yin, Z. Miao, H. Yu, C. Chen, Z. Zhang, J. Wang, and Y. Li. 2013b. The inhibition of metastasis and growth of breast cancer by blocking the NF-kB signaling pathway using bioreducible PEI-based/p65 shRNA complex nanoparticles. Biomaterials 34: 5381-5390.
110. Yao, V.J., M.G. Ozawa, M. Trepel, W. Arap, D.M. McDonald, and R. Pasqualini. 2005. Targeting pancreatic islets with phage display assisted by laser pressure catapult microdissection. American Journal of Pathology 166: 625-636.
111. Yin, Q., J. Shen, Z. Zhang, H. Yu, L. Chen, W. Gu, and Y. Li. 2013. Multifunctional nanoparticles improve therapeutic effect for breast cancer by simultaneously antagonizing multiple mechanisms of multidrug resistance. Biomacromolecules 14: 2242-2252.
112. Yoshino, T., H. Shiina, S. Urakami, N. Kikuno, T. Yoneda, K. Shigeno, and M. Igawa. 2006. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clinical Cancer Research 12: 6116-6124.
113. Zhang, P.-H., L. Zou, and Z.-G. Tu. 2006. RNAi-hTERT inhibition hepatocellular carcinoma cell proliferation via decreasing telomerase activity. Journal of Surgical Research 131: 143-149.
114. Zhou, Q.-H., C. Wu, D.S. Manickam, and D. Oupicky. 2009. Evaluation of pharmacokinetics of bioreducible gene delivery vectors by real-time PCR. Pharmaceutical Research 26: 1581-1589.